financetom
Business
financetom
/
Business
/
Logistics provider Hub Group's Q3 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Logistics provider Hub Group's Q3 revenue beats estimates
Oct 30, 2025 1:43 PM

Overview

* Hub Group ( HUBG ) Q3 revenue of $934 mln beats analyst expectations

* Adjusted EPS of $0.49 misses analyst expectations

* Company had completed acquisitions of Marten Transport Intermodal assets and SITH, LLC

Outlook

* Hub Group ( HUBG ) expects 2025 EPS to range from $1.80 to $1.90

* Company estimates 2025 revenue of $3.6 bln to $3.7 bln

* Hub Group ( HUBG ) projects 2025 capital expenditures under $50 mln

Result Drivers

* INTERMODAL GROWTH - Stable intermodal volume and increased revenue per load contributed positively to results

* COST MANAGEMENT - Expense management helped offset lower revenue impact

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $934.49 $926.11

Revenue mln mln (12

Analysts

)

Q3 EPS Miss $0.47 $0.48

(16

Analysts

)

Q3 Net $28.92

Income mln

Q3 Beat $88 mln $80.09

Adjusted mln (12

EBITDA Analysts

)

Q3 Capex $9 mln

Q3 $39.44

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the ground freight & logistics peer group is "buy"

* Wall Street's median 12-month price target for Hub Group Inc ( HUBG ) is $39.00, about 8.4% above its October 29 closing price of $35.72

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved